Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form
Reexamination Certificate
2006-05-09
2006-05-09
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
C424S422000, C424S464000, C514S821000, C514S256000, C514S269000, C514S393000, C514S398000, C514S399000
Reexamination Certificate
active
07041303
ABSTRACT:
A method of treating myocardial damage secondary to myocardial infarction using moxonidine or a physiologically compatible salt thereof. Pharmaceutical preparations containing moxonidine and its physiologically compatible acid addition salts are suitable for use in acute myocardial infarction and/or postmyocardial infarction management. In addition to a beneficial influence, promoting recovery and/or rehabilitation, on the myocardial status following myocardial infarction, moxonidine and its physiologically compatible acid addition salts, especially when used in the management of postmyocardial infarction patients in the chronic stage, also show a preventive effect against the progression of heart failure after myocardial infarction.
REFERENCES:
patent: 0317855 (1990-08-01), None
patent: WO9746241 (1997-12-01), None
Howes et al. Comparative effects of angiotensin converting enzyme inhibition (perindopril) or diuretic therapy on cardiac hypertrophy and sympathetic activity following myocardial infarction in rats. Cardiovascular Drug Therapy, Feb., 1991, 5(1):147-152.
Rene Roland Wenzel, “I1-Imidazoline Agonist Moxonidine Decrease Sympathetic Nerve Activity and Blood Pressure in Hypertensives” Hypertension, Dec. 1998.
W. Lada, “Imidazoline-prefering receptors and the I1-imidazoline blocking therapy” Pol. Merk. Lek., 1996.
Istvan Lepran, “Effect of Moxonidine on Arrhythmias Induced by Coronary Artery Occlusion and Reperfusion” Journal of Cardiovascular Pharmacology, 1994.
Channavajjala Lakshmi
Crowell & Moring LLP
Page Thurman K.
Solvay Pharmaceuticals GmbH
LandOfFree
Use of moxonidine for postmyocardial infarction treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of moxonidine for postmyocardial infarction treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of moxonidine for postmyocardial infarction treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3530348